Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously withou...
Saved in:
Published in: | Journal of psychoactive drugs Vol. 51; no. 2; pp. 189 - 198 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Taylor & Francis
01-04-2019
Haight Ashbury Publications |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as undesirable "side effects." In contrast, we believe ketamine can benefit patients with a wide variety of diagnoses when administered with psychotherapy and using its psychedelic properties without need for intravenous (IV) access. Its proven safety over decades of use makes it ideal for office and supervised at-home use. The unique experience that ketamine facilitates with its biological, experiential, and psychological impacts has been tailored to optimize office-based treatment evolving into a method that we call Ketamine Assisted Psychotherapy (KAP). This article is the first to explore KAP within an analytical framework examining three distinct practices that use similar methods. Here, we present demographic and outcome data from 235 patients. Our findings suggest that KAP is an effective method for decreasing depression and anxiety in a private practice setting, especially for older patients and those with severe symptom burden. |
---|---|
AbstractList | Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as undesirable "side effects." In contrast, we believe ketamine can benefit patients with a wide variety of diagnoses when administered with psychotherapy and using its psychedelic properties without need for intravenous (IV) access. Its proven safety over decades of use makes it ideal for office and supervised at-home use. The unique experience that ketamine facilitates with its biological, experiential, and psychological impacts has been tailored to optimize office-based treatment evolving into a method that we call Ketamine Assisted Psychotherapy (KAP). This article is the first to explore KAP within an analytical framework examining three distinct practices that use similar methods. Here, we present demographic and outcome data from 235 patients. Our findings suggest that KAP is an effective method for decreasing depression and anxiety in a private practice setting, especially for older patients and those with severe symptom burden. |
Author | Andries, Julane Strauss, Nicole Huidekoper, Angela Turnipseed, Andrea Wolfson, Phil Monnette, Celeste Dore, Jennifer Ascani, German Dwyer, Shannon Turnipseed, Brent |
Author_xml | – sequence: 1 givenname: Jennifer surname: Dore fullname: Dore, Jennifer organization: Helios Psychiatry – sequence: 2 givenname: Brent surname: Turnipseed fullname: Turnipseed, Brent organization: Roots Behavioral Health – sequence: 3 givenname: Shannon surname: Dwyer fullname: Dwyer, Shannon organization: Helios Psychiatry – sequence: 4 givenname: Andrea surname: Turnipseed fullname: Turnipseed, Andrea organization: Roots Behavioral Health – sequence: 5 givenname: Julane surname: Andries fullname: Andries, Julane organization: Center for Transformational Psychotherapy – sequence: 6 givenname: German surname: Ascani fullname: Ascani, German organization: Center for Transformational Psychotherapy – sequence: 7 givenname: Celeste surname: Monnette fullname: Monnette, Celeste organization: Center for Transformational Psychotherapy – sequence: 8 givenname: Angela surname: Huidekoper fullname: Huidekoper, Angela organization: Ketamine Research Foundation – sequence: 9 givenname: Nicole surname: Strauss fullname: Strauss, Nicole organization: Ketamine Research Foundation – sequence: 10 givenname: Phil surname: Wolfson fullname: Wolfson, Phil email: ketamine.research@gmail.com organization: Ketamine Research Foundation |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30917760$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kctqGzEUQEVJaZy0n9Ai6CaFjqvHaCR1VeP0RQzxIl0LWdJ4FGYkR5IJ_pV-bWewE2gXXWlxz71HcC7AWYjBAfAWozlGAn1ChEuMOJkThOUcM8EZa16AGcFMVpJzfgZmE1NN0Dm4yPkeIdSQpnkFzimSmPMGzcDvG1f04IODi5x9Ls7CdT6YLpbOJb07wKubxfrDZ7jWxbtQ4LUb4nYcdN7kj3DZ--CN7uG1LhrqYOHtvpg4uAx9gHddcg6udNo6uE7aFG_GwcKOusmUfNjCZ_2jL93f6tfgZav77N6c3kvw69vXu-WPanX7_edysapMXeNSUWcxddSKBjFe27Y2DGPLBBaCUCQYMZZtDG2Q2FiCiGbCtZJtBGpFKy1j9BJcHe_uUnzYu1zU4LNxfa-Di_usCJYSC86pHNH3_6D3cZ_C-DtFCCWE17RGI8WOlEkx5-RatUt-0OmgMFJTPPUUT03x1CneuPfudH2_GZx93nqqNQJfjoAPbUyDfoypt6roQx9Tm3QwPiv6f8cfB9erDA |
CitedBy_id | crossref_primary_10_1080_02791072_2021_1957183 crossref_primary_10_17744_mehc_42_4_03 crossref_primary_10_31640_2706_8803_2022__3_4__04 crossref_primary_10_1080_17512433_2021_1933434 crossref_primary_10_3389_fpsyt_2024_1398859 crossref_primary_10_1124_pr_119_018697 crossref_primary_10_3390_brainsci12030382 crossref_primary_10_3389_fpsyt_2023_1197697 crossref_primary_10_3389_fphar_2022_916641 crossref_primary_10_1007_s10615_019_00743_x crossref_primary_10_1016_j_heliyon_2023_e15883 crossref_primary_10_1111_jmwh_13371 crossref_primary_10_3928_00485713_20220810_04 crossref_primary_10_1192_bjo_2021_1061 crossref_primary_10_1080_17512433_2020_1772054 crossref_primary_10_1186_s40345_022_00265_5 crossref_primary_10_2217_cer_2022_0149 crossref_primary_10_1172_JCI180217 crossref_primary_10_1192_bjp_2022_58 crossref_primary_10_2147_JPR_S360733 crossref_primary_10_3389_fpsyt_2024_1209419 crossref_primary_10_1080_28376811_2024_2371792 crossref_primary_10_1089_psymed_2023_0002 crossref_primary_10_1523_JNEUROSCI_1659_20_2020 crossref_primary_10_3389_fnhum_2023_1200393 crossref_primary_10_1017_S1478951522001304 crossref_primary_10_1007_s00213_023_06388_6 crossref_primary_10_1080_14740338_2022_2069749 crossref_primary_10_1186_s40337_022_00588_9 crossref_primary_10_1080_18387357_2023_2235030 crossref_primary_10_3389_fpsyt_2022_865466 crossref_primary_10_1038_s41467_020_20190_4 crossref_primary_10_3389_fpsyt_2021_710338 crossref_primary_10_3389_fpsyt_2021_695335 crossref_primary_10_1016_j_encep_2021_08_011 crossref_primary_10_3389_fpsyt_2023_1268832 crossref_primary_10_1177_0269881121997099 crossref_primary_10_1080_02791072_2019_1606472 crossref_primary_10_1038_s44220_023_00140_x crossref_primary_10_1080_02791072_2023_2253798 crossref_primary_10_1089_psymed_2023_0071 crossref_primary_10_1093_ijnp_pyaa018 crossref_primary_10_1227_neu_0000000000002275 crossref_primary_10_1016_j_jcbs_2019_11_001 crossref_primary_10_1016_j_jad_2022_06_036 crossref_primary_10_1017_S147895152300069X crossref_primary_10_1177_1534650121990894 crossref_primary_10_1016_j_jad_2021_12_097 crossref_primary_10_1007_s00213_023_06324_8 crossref_primary_10_1080_02791072_2024_2341811 crossref_primary_10_3389_fpsyt_2023_1246891 crossref_primary_10_3389_fpsyg_2022_868103 crossref_primary_10_1038_s41386_023_01666_5 crossref_primary_10_3389_fpsyt_2021_803279 crossref_primary_10_22374_jmhan_v4i1_40 crossref_primary_10_1016_j_jpsychires_2022_04_037 crossref_primary_10_1016_j_tips_2021_08_003 crossref_primary_10_3389_fpsyt_2022_992624 crossref_primary_10_3390_psych4010012 crossref_primary_10_1080_02791072_2022_2154722 crossref_primary_10_3389_fpsyt_2022_948115 crossref_primary_10_1192_bjo_2023_53 crossref_primary_10_1177_0269881121998321 crossref_primary_10_1097_HRP_0000000000000330 crossref_primary_10_1007_s00213_022_06083_y crossref_primary_10_1186_s12888_022_04268_5 crossref_primary_10_1080_02791072_2023_2248989 crossref_primary_10_1016_j_jad_2022_09_083 crossref_primary_10_1080_02791072_2022_2101903 crossref_primary_10_1007_s00213_021_05825_8 crossref_primary_10_1097_YIC_0000000000000363 crossref_primary_10_1177_20451253231171512 crossref_primary_10_31392_NPU_nc_series15_2023_10_170__32 crossref_primary_10_1080_02791072_2021_1912863 crossref_primary_10_3389_fnins_2023_1197409 crossref_primary_10_1007_s00213_021_06027_y crossref_primary_10_4102_sajpsychiatry_v30i0_2176 crossref_primary_10_3389_fpsyt_2022_1020214 crossref_primary_10_1080_02791072_2023_2186285 crossref_primary_10_1176_appi_ajp_2019_19010035 crossref_primary_10_1007_s43440_021_00232_4 crossref_primary_10_1007_s44192_022_00012_3 crossref_primary_10_3389_fpsyt_2023_1141988 crossref_primary_10_1089_psymed_2023_0021 crossref_primary_10_1089_cap_2021_0078 crossref_primary_10_1093_ijnp_pyae017 crossref_primary_10_1177_02698811221140011 crossref_primary_10_1176_appi_focus_19104 crossref_primary_10_3389_fpsyt_2023_1214018 crossref_primary_10_1016_j_encep_2022_08_011 crossref_primary_10_1016_j_jad_2023_04_019 crossref_primary_10_1016_j_neuropharm_2022_109375 crossref_primary_10_1055_a_1981_3152 crossref_primary_10_1521_pdps_2023_51_4_467 crossref_primary_10_1556_2054_2022_00211 crossref_primary_10_1016_j_jad_2024_05_131 crossref_primary_10_1007_s11469_023_01160_5 crossref_primary_10_1016_j_neubiorev_2023_105410 crossref_primary_10_3390_bs11090118 crossref_primary_10_1007_s00278_024_00710_z crossref_primary_10_3389_fpsyt_2021_764112 crossref_primary_10_1093_ijnp_pyae024 crossref_primary_10_1177_23982128211007772 crossref_primary_10_3389_fpsyg_2021_645246 crossref_primary_10_1556_2054_2021_00179 crossref_primary_10_1016_j_euroneuro_2022_09_004 crossref_primary_10_1177_02698811221084055 crossref_primary_10_1007_s40263_022_00897_2 crossref_primary_10_1016_j_jad_2022_07_030 |
Cites_doi | 10.1016/S0033-3182(73)71306-2 10.1001/archpsyc.1994.03950030035004 10.4103/0253-7176.127258 10.1007/s00213-017-4779-2 10.1111/nyas.12223 10.1080/02791072.1997.10400185 10.1017/S0033291714001603 10.24972/ijts 10.1177/0269881118754710 10.1007/s00213-011-2358-5 10.1007/978-3-319-42925-0 10.1016/j.jad.2014.02.017 10.1016/j.biopsych.2009.08.038 10.3389/fnhum.2016.00269.eCollection2016 10.1017/S1461145713000485 10.3389/fpsyg.2018.01475 10.1016/S0006-3223(99)00230-9 10.1176/appi.ajp.2012.12020219 10.1016/S2215-0366(15)00576-3 10.1038/sj.npp.1300994 10.1176/appi.ajp.2018.18020138 |
ContentType | Journal Article |
Copyright | 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. |
Copyright_xml | – notice: 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 – notice: 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. |
DBID | 0YH CGR CUY CVF ECM EIF NPM AAYXX CITATION K7. K9. NAPCQ 7X8 |
DOI | 10.1080/02791072.2019.1587556 |
DatabaseName | Taylor & Francis (Open Access) Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Criminal Justice (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium ProQuest Criminal Justice (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work Psychology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2159-9777 |
EndPage | 198 |
ExternalDocumentID | 10_1080_02791072_2019_1587556 30917760 1587556 |
Genre | Articles Multicenter Study Journal Article |
GrantInformation_xml | – fundername: None of the authors of this paper have a financial interest or benefit arising from the direct applications of this research |
GroupedDBID | --- -DZ -~X .7I .QK 07V 0BK 0R~ 0YH 29L 36B 4.4 53G 5GY 5RE 6PF 7RV 85S 8R4 8R5 AAGZJ AAJNR AALUX AAMIU AAPUL AAQRR AAWTL ABBKH ABDBF ABEIZ ABIVO ABLCE ABPEM ABPTK ABTAI ABUPF ACENM ACGFO ACGFS ACGOD ACHQT ACLSK ACNCT ACTOA ACVOX ADCVX ADFCX AECIN AEKEX AEOZL AFOLD AFWLO AGDLA AGFJD AGMYJ AGRBW AGYJP AHMBA AIJEM AIRBT AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU AMDAE ARJSQ AVBZW BLEHA BMOTO BOHLJ CCCUG CQ1 DGFLZ DKSSO EAP EAS EBS EJD EMB EMK EMOBN ESX E~B E~C F5P F8P FUNRP G-F GTTXZ H13 HF~ HZ~ IPNFZ J.O KDLKA KUULJ KYCEM LJTGL M4Z NA5 NZ~ O9- P2P Q2X RNANH RVRKI RWL RXW S-F STATR SV3 TAE TFL TFW TN5 TNTFI TUS UC6 UEQFS UT5 UT9 V1K WH7 YCJ ZCA ~01 ~S~ .GJ 0-V 0VX 3V. 7X7 88E 88I 8AF 8AO 8FI 8FJ 8FW AAIAR AAORF ABFIM ABJNI ABLIJ ABUWG ABWCV ABXYU ABZEW ACBNA ACIEZ ACKZS ADBBV ADFOM ADFZZ AEIIZ AFFNX AFKRA AFLEI AJSLH AJVHN ALIPV ALSLI ALYBC AMATQ ARALO AZQEC BENPR BGRYB BKEYQ BPHCQ BRMBE BVXVI C04 CCPQU CGR CUY CVF CYYVM CZDIS DMVAR DRXRE DWQXO DWTOO ECM EIF EX3 FYUFA G8K GNUQQ HCIFZ HMCUK H~9 JENTW M0O M1P M2M M2P M2Q NAPCQ NPM NUSFT OHT PQQKQ PROAC PSQYO PSYQQ QQXMO RIG S0X TBQAZ TDBHL TERGH TUROJ UKHRP WOW ZCG ZGI ZXP AAYXX CITATION K7. K9. 7X8 |
ID | FETCH-LOGICAL-c441t-3ed13e3d860574df4c511d58188230852cd5bc3608bd202a58ef95b80f8f9d553 |
IEDL.DBID | TFW |
ISSN | 0279-1072 |
IngestDate | Fri Oct 25 22:06:55 EDT 2024 Mon Nov 04 11:26:53 EST 2024 Fri Aug 23 04:03:39 EDT 2024 Wed Oct 16 00:45:05 EDT 2024 Tue Jun 13 19:51:39 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | PTSD psychedelics Depression psychotherapy ketamine psychedelic psychotherapy |
Language | English |
License | open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c441t-3ed13e3d860574df4c511d58188230852cd5bc3608bd202a58ef95b80f8f9d553 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.tandfonline.com/doi/abs/10.1080/02791072.2019.1587556 |
PMID | 30917760 |
PQID | 2232274340 |
PQPubID | 41415 |
PageCount | 10 |
ParticipantIDs | informaworld_taylorfrancis_310_1080_02791072_2019_1587556 pubmed_primary_30917760 crossref_primary_10_1080_02791072_2019_1587556 proquest_miscellaneous_2199187739 proquest_journals_2232274340 |
PublicationCentury | 2000 |
PublicationDate | 2019 Apr-Jun |
PublicationDateYYYYMMDD | 2019-04-01 |
PublicationDate_xml | – month: 04 year: 2019 text: 2019 Apr-Jun |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Oxford |
PublicationTitle | Journal of psychoactive drugs |
PublicationTitleAlternate | J Psychoactive Drugs |
PublicationYear | 2019 |
Publisher | Taylor & Francis Haight Ashbury Publications |
Publisher_xml | – name: Taylor & Francis – name: Haight Ashbury Publications |
References | Early T. (CIT0006) 2016 Brown D. A. (CIT0001) 2016 Wieber J. (CIT0034) 1975; 24 Weber F. (CIT0033) 2004; 14 Hyde S. J. (CIT0010) 2015 Fontana A. (CIT0008) 1974; 20 CIT0014 CIT0013 CIT0035 CIT0038 CIT0015 CIT0018 Jansen K. (CIT0012) 2004 CIT0017 CIT0019 Yensen R. (CIT0037) 2016 CIT0021 Krystal J. H. (CIT0016) 2007; 137 CIT0020 CIT0023 CIT0022 Ryan W. (CIT0028) 2016 Wolfson P. (CIT0036) 2016 Van Der Kolk B. (CIT0031) 2014 Jaitly V. (CIT0011) 2013; 1 CIT0003 CIT0025 CIT0002 CIT0024 Schwartz R. (CIT0029) 1995 CIT0005 CIT0027 CIT0004 CIT0026 CIT0007 CIT0009 |
References_xml | – ident: CIT0013 doi: 10.1016/S0033-3182(73)71306-2 – ident: CIT0017 doi: 10.1001/archpsyc.1994.03950030035004 – ident: CIT0003 doi: 10.4103/0253-7176.127258 – ident: CIT0007 doi: 10.1007/s00213-017-4779-2 – ident: CIT0038 doi: 10.1111/nyas.12223 – ident: CIT0015 doi: 10.1080/02791072.1997.10400185 – volume-title: Ketamine: Dreams and realities year: 2004 ident: CIT0012 contributor: fullname: Jansen K. – ident: CIT0022 doi: 10.1017/S0033291714001603 – volume-title: Internal family systems therapy year: 1995 ident: CIT0029 contributor: fullname: Schwartz R. – volume: 20 start-page: 32 year: 1974 ident: CIT0008 publication-title: Acta psiquiatrica y psicologica de America latina contributor: fullname: Fontana A. – ident: CIT0014 doi: 10.24972/ijts – volume-title: The ketamine papers year: 2016 ident: CIT0036 contributor: fullname: Wolfson P. – volume-title: The body keeps the score year: 2014 ident: CIT0031 contributor: fullname: Van Der Kolk B. – ident: CIT0002 doi: 10.1177/0269881118754710 – volume: 137 start-page: 215 issue: 15 year: 2007 ident: CIT0016 publication-title: Swiss Medical Weekly contributor: fullname: Krystal J. H. – ident: CIT0009 doi: 10.1007/s00213-011-2358-5 – ident: CIT0021 doi: 10.1007/978-3-319-42925-0 – start-page: 305 volume-title: The ketamine papers: Science,therapy and transformation year: 2016 ident: CIT0006 contributor: fullname: Early T. – ident: CIT0020 doi: 10.1016/j.jad.2014.02.017 – ident: CIT0027 doi: 10.1016/j.biopsych.2009.08.038 – volume: 14 start-page: 983 issue: 12 year: 2004 ident: CIT0033 publication-title: Paediatr†anaesth contributor: fullname: Weber F. – ident: CIT0025 doi: 10.3389/fnhum.2016.00269.eCollection2016 – start-page: 69 volume-title: The ketamine papers year: 2016 ident: CIT0037 contributor: fullname: Yensen R. – ident: CIT0019 doi: 10.1017/S1461145713000485 – ident: CIT0023 doi: 10.3389/fpsyg.2018.01475 – volume-title: Ketamine and depression year: 2015 ident: CIT0010 contributor: fullname: Hyde S. J. – volume-title: Attachment disorder in adults year: 2016 ident: CIT0001 contributor: fullname: Brown D. A. – ident: CIT0026 doi: 10.1016/S0006-3223(99)00230-9 – start-page: 199 volume-title: The ketamine papers year: 2016 ident: CIT0028 contributor: fullname: Ryan W. – ident: CIT0005 doi: 10.1176/appi.ajp.2012.12020219 – ident: CIT0024 doi: 10.1016/S2215-0366(15)00576-3 – volume: 1 issue: 2013 year: 2013 ident: CIT0011 publication-title: Journal of Observational Pain Medicine contributor: fullname: Jaitly V. – ident: CIT0018 doi: 10.1038/sj.npp.1300994 – ident: CIT0004 doi: 10.1016/j.biopsych.2009.08.038 – volume: 24 start-page: 260 issue: 6 year: 1975 ident: CIT0034 publication-title: Anaesthesist contributor: fullname: Wieber J. – ident: CIT0035 doi: 10.1176/appi.ajp.2018.18020138 |
SSID | ssj0006266 |
Score | 2.562485 |
Snippet | Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several... |
SourceID | proquest crossref pubmed informaworld |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 189 |
SubjectTerms | Adult Anxiety - therapy Clinical outcomes Combined Modality Therapy Demographics Depression Depression - therapy Drug therapy Female Hallucinogens - administration & dosage Humans Ketamine Ketamine - administration & dosage Male Mental depression psychedelic psychotherapy psychedelics Psychotherapy Psychotherapy - methods Psychotropic drugs PTSD Retrospective Studies |
Title | Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy |
URI | https://www.tandfonline.com/doi/abs/10.1080/02791072.2019.1587556 https://www.ncbi.nlm.nih.gov/pubmed/30917760 https://www.proquest.com/docview/2232274340 https://search.proquest.com/docview/2199187739 |
Volume | 51 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELZaeuHSB32wdIumUoVaiUBeXju9rdhdIdHSSN2K3iIntiVUyKJN9rB_pb-2M3ES2APqAY5J7Hgsf7Y_2zOfGfukSFMk1tLz40iRqLb08gL7VY7YMaHASVBToPDpT3H-W06mJJMz7mJhyK2S1tDWCUU0YzV1bpVXnUfcMa6kcJITFEYVJEcBR8rNSXSbNLcR0fPZRT8WI11vTisxh0dZuhie-_6yMTttaJfez0CbmWj24hHq8JI9b2kojB1uXrEnptxhB6nTsV4fwvw2LKs6hANIbxWu1ztsux828WHoInzhwlxZtTSYuHuxWP55zf6emVpdo4GASCBMaUjvRH6t4fPZOP3yFVIn8AoTc-1UtJuSW9nSK5ioWgHWFn6saqypqeCyRCuXxsA3cmaHtA33qqDTA25EFqEvnnacN4t-w37NpvOTU6-9EMIrkLXVXmQ0bdpqiWswEWsbF0gXNUfOQceFkoeF5oi0kS9zHfqh4tLYhOfSt9ImmvPoLdsqF6XZZZAUATdBZEMjbBzIPA-UKXKlRiPka0hjB-yoA0J243Q_sqCTU23bLqO2y9q2G7DkLlyyutlwse52lCz6T95hh62sHUKqDHlbGCK_i_0B-9h_xs5PJzqqNIsVpiHHNSlElAzYO4fJ3toImaAQI3_vAYa9Z9v06DyVhmyrXq7MB_a00qt99mx8Mj3_vt_0t392ISU3 |
link.rule.ids | 315,782,786,1455,1509,27935,27936,58024,59737,59871,60526,60660 |
linkProvider | Taylor & Francis |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFD5i2wN74TJuhQIHCU0gLSM3Jw5v1dqpqF2JRBG8WU7sSIgtRU360L_Cr-U4TrL1YeIBHpPYsS1_Pv5sn_MZ4K00miKh4o4bBtKIanMny2lcZYQd7cc0CSoTKDz9Ei--8_HEyOT0sTDGrdKsoQsrFNHYajO4zWZ05xL3gZZSNMvFJo7KS049RpybRXtwwGgBTYPzYHQ2WVz09pgoe3NiSZkck6uL47ntRzsz1I5-6e0stJmNzu__j3Y8gHstF8WRBc9DuKPLIzhOrZj19gSX17FZ1QkeY3otc709gsPedtLD0Ib54jd9Wci1psTdi9X65yP4PdO1vKIaIsHBAEtheiP8a4vvZqP0_UdMrcorjvWVldJuSm61Sy9xLGuJ1Fz8vKmpqbrCHyXVcq01zo1HO6ZtzFeFnShwo7SIffFm23m36Mfw9XyyPJs67a0QTk7UrXYCrczOreK0EItDVYQ5cUbFiHiYM0PO_Fwxglvk8kz5ri8Z10XCMu4WvEgUY8ET2C9XpX4GmOQe015Q-DouQo9nmSd1nkkZRUTaiMsO4LRDgvhlxT-E12mqtn0nTN-Jtu8GkNzEi6ibXZfCXpEigr_kHXbgEq0dqQSRN98nkhe6A3jTfyYLYI51ZKlXG0pjvNd4HAfJAJ5aUPa1DYgOxnHkPv-Hir2Gu9PlxVzMPy1mL-DQfLKuS0PYr9cb_RL2KrV51Q67P9vaKMA |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB7RIqFeeJTXwgKDhCqQmpKXE4fbiu2qaKsSiUXlZjmxLSHabLXJHvav8GsZx0naPVQc4JjEjm35s-ezPfMZ4J20miKx4p4fR9KKanOvKGlcFYQdHaZkBJUNFD75lp794NNjK5Mz6WNhrFulXUMbJxTRztV2cF8p03vEfaSVFBm51IZRBdlRwIhys2QH7jJOBocgvZidD5Mx8fX2uJKyeDZPH8Rz22-2zNOWeOntFLQ1RbMH_6ERD-F-x0Nx4oDzCO7oah8OcidkvTnExXVcVn2IB5hfS1xv9mFvmDfpYexCfPFcXxi50pS4f7Fc_XoMv-e6kZdUQSQoWFApzG-Efm3w_XySf_iEuVN4xam-dDLabcmdbukFTmUjkVqLX9cNtVTX-LOiWq60xlPrzY55F-9VYy8I3Kos4lC83XLeLvoJfJ8dLz6feN2NEF5JtK3xIq3srq3itAhLY2XikviiYkQ67HkhZ2GpGEEt8XmhQj-UjGuTsYL7hptMMRY9hd1qWenngFkZMB1EJtSpiQNeFIHUZSFlkhBhIx47gqMeCOLKCX-IoNdT7fpO2L4TXd-NILsJF9G0Oy7GXY8ior_kHffYEt0cUgsibmFIBC_2R_B2-Eyj3x7pyEov15TGeq7xNI2yETxzmBxqGxEVTNPEf_EPFXsD9_LpTJx-OZu_hD37xXktjWG3Wa31K9ip1fp1O-T-AOV0Jns |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ketamine+Assisted+Psychotherapy+%28KAP%29%3A+Patient+Demographics%2C+Clinical+Data+and+Outcomes+in+Three+Large+Practices+Administering+Ketamine+with+Psychotherapy&rft.jtitle=Journal+of+psychoactive+drugs&rft.au=Dore%2C+Jennifer&rft.au=Turnipseed%2C+Brent&rft.au=Dwyer%2C+Shannon&rft.au=Turnipseed%2C+Andrea&rft.date=2019-04-01&rft.pub=Taylor+%26+Francis&rft.issn=0279-1072&rft.eissn=2159-9777&rft.volume=51&rft.issue=2&rft.spage=189&rft.epage=198&rft_id=info:doi/10.1080%2F02791072.2019.1587556&rft.externalDBID=0YH&rft.externalDocID=1587556 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0279-1072&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0279-1072&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0279-1072&client=summon |